Director Mateo Alan bought 40,000 TXG shares at $11.14 (Feb 21), now -76.4% from 52-week high; co. unprofitable
Mateo Alan, a Director of 10x Genomics, purchased 40,000 shares at $11.14 on 2025-02-21 for $445,572.00, expanding his holdings by 184.4% to 61,691 shares. The purchase occurred at a stock price significantly depressed from the 52-week high of $47.16, with the stock currently trading 76.4% below that peak and down 25.0% in the prior 30 days. The company's fundamentals show deterioration: it is unprofitable with negative net income of -$35.8M against quarterly revenue of $151.7M, and annual revenue growth declined -1.3%. Across his broader trading history, Alan's prior 7 open-market sells achieved a 57.14% well-timed rate, suggesting a pattern of disciplined exit timing; this buy represents a substantial accumulation at depressed valuations against that backdrop.